Subscribe to RSS
DOI: 10.1055/s-0032-1325934
Die perkutane „edge-to-edge“-Reparatur der Mitralklappeninsuffizienz mit dem MitraClip-System
Publication History
Publication Date:
20 December 2012 (online)
![](https://www.thieme-connect.de/media/kardiologie-u2d/201204/lookinside/thumbnails/10.1055-s-0032-1325934-1.jpg)
Abstract
Mitral regurgitation (MR) is the second most frequent valve disease world wide and comprises organic or primary and functional or secondary MR. Secondary MR is caused by pathologic remodeling of the left ventricle or valve apparatus, and mostly affects an elder population with severe co-morbidities. This common manifestation of MR contributes to the poor prognosis of such patients. Therapeutic options for the treatment of patients with chronic ischemic MR are limited, current guidelines are based on weak evidences and the optimal treatment is still a matter of controversy. Surgical correction of secondary MR is only advised in patients with indication for concomitant surgical revascularization. The MitraClip procedure is a new interventional approach aiming to reduce MR by direct edge-to-edge repair of the diseased valve. Current evidence confirms the safety and efficacy of this method in selected patient populations. This minimal invasive therapy is a new treatment option for high-risk, non-surgical patients with relevant MR.
-
Literatur
- 1 Nkomo VT, Gardin JM, Skelton TN et al. Burden of valvular heart diseases: a population-based study. Lancet 2006; 368: 1005-1011
- 2 Vahanian A, Alfieri O, Andreotti F et al. Guidelines on the management of valvular heart disease (version 2012): The Joint Task Force on the Management of Valvular Heart Disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 2012; 33: 2451-2496
- 3 Bach DS, Awais M, Gurm HS et al. Failure of guideline adherence for intervention in patients with severe mitral regurgitation. J Am Coll Cardiol 2009; 54: 860-865
- 4 Mirabel M, Iung B, Baron G et al. What are the characteristics of patients with severe, symptomatic, mitral regurgitation who are denied surgery?. Eur Heart J 2007; 28: 1358-1365
- 5 Feldman T, Kar S, Rinaldi M et al. Percutaneous mitral repair with the MitraClip system: safety and midterm durability in the initial EVEREST (Endovascular Valve Edge-to-Edge REpair Study) cohort. J Am Coll Cardiol 2009; 54: 686-694
- 6 Feldman T, Foster E, Glower DD et al. Percutaneous repair or surgery for mitral regurgitation. N Engl J Med 2011; 364: 1395-1406
- 7 Whitlow PL, Feldman T, Pedersen WR et al. Acute and 12-month results with catheter-based mitral valve leaflet repair: the EVEREST II (Endovascular Valve Edge-to-Edge Repair) High Risk Study. J Am Coll Cardiol 2012; 59: 130-139
- 8 Auricchio A, Schillinger W, Meyer S et al. Correction of mitral regurgitation in nonresponders to cardiac resynchronization therapy by MitraClip improves symptoms and promotes reverse remodeling. J Am Coll Cardiol 2011; 58: 2183-2189
- 9 Franzen O, Baldus S, Rudolph V et al. Acute outcomes of MitraClip therapy for mitral regurgitation in high-surgical-risk patients: emphasis on adverse valve morphology and severe left ventricular dysfunction. Eur Heart J 2010; 31: 1373-1381
- 10 Franzen O, van der Heyden HJ, Baldus S et al. MitraClip(R) therapy in patients with end-stage systolic heart failure. Eur J Heart Fail 2011; 13: 569-576